Oral semaglutide (Rybelsus) lowered the risk for major adverse cardiovascular events (MACEs) by a significant 14% compared with placebo, Novo Nordisk announced. The topline results met the primary endpoint of the company’s multicenter, double-blinded, randomized SOUL trial of 9650 people with type 2 diabetes (T2D) and established cardiovascular disease and/or chronic kidney disease...
.png)
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved
